This is an early-phase clinical study investigating a new combination treatment, Ris-Rez given with ivonescimab for adults with advanced solid cancers. The study aims to determine: * What dose(s) of Ris-Rez given with ivonescimab is safe and what are the side effects? * How does the body handle the drug(s)? * What dose of Ris-Rez given with ivonescimab may work best and can improve the treatment of cancer?
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Confirmed Objective Response Rate (cORR)
Timeframe: Up to approximately 143 weeks
Number of participants with Adverse events (AEs), Serious Adverse Events (SAEs) and Adverse events of special interest (AESIs) by severity
Timeframe: Up to approximately 143 weeks
Number of participants with AEs leading to dose modifications or study intervention discontinuation
Timeframe: Up to approximately 130 weeks
Number of participants with changes in safety parameters
Timeframe: Up to approximately 143 weeks
Number of participants with Dose Limiting Toxicities (DLT)
Timeframe: Up to 21 days
Number of participants with a change from baseline in vital signs
Timeframe: Baseline (Day -1) and up to approximately 143 weeks
Number of participants with a change from baseline in body weight
Timeframe: Baseline (Day -1) and up to approximately 143 weeks
Number of participants with a change from baseline in laboratory parameters (hematology, clinical chemistry and urinalysis)
Timeframe: Baseline (Day -1) and up to approximately 143 weeks
Number of participants with a change from baseline in cardiac function [Electrocardiogram (ECG) and Echocardiogram (ECHO)
Timeframe: Baseline (Day -1) and up to approximately 143 weeks
Number of participants with a change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status
Timeframe: Baseline (Day -1) and up to approximately 143 weeks